Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

ALLERGAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. - AGNOpen in a New Window

NEW ORLEANS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24AGN&src=ctag" target="_blank"gt;$AGNlt;/agt; lt;a href="https://twitter.com/hashtag/AGN?src=hash" target="_blank"gt;#AGNlt;/agt;--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc. (NYSE: AGN), if they purchased the Company’s shares between February 24, 2017, and December 19, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the South

 

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Open in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 76,000 shares of Kala Pharmaceuticals common stock to twelve new employees. The stock options were granted on January 15, 2019. The grant was approve

 

MEDIA ADVISORY: Fabric Genomics™ Senior Scientist to Discuss Role of Genomics and Artificial Intelligence in Advancing Precision Medicine – Tuesday, January 22ndOpen in a New Window

OAKLAND, Calif.--(BUSINESS WIRE)--Fabric Genomics™ senior scientist discusses how AI can enhance genomics' value in advancing precision medicine

 

Navitus Launches a New Website and Refreshed Brand to Further Its Mission to Make Prescription Benefits More AffordableOpen in a New Window

MADISON, Wis.--(BUSINESS WIRE)--Navitus Health Solutions, a full-service prescription benefit manager (PBM), is pleased to announce the launch of its new website and refreshed brand at www.navitus.com. The new site features a modern design, improved functionality and easy access to essential information to help benefit purchasers make well-informed prescription benefit decisions. The site will also more effectively convey the company’s mission and capabilities as it continues to make prescripti

 

Photo of Cigna Building Blessings in a Backpack in Phoenix Available on Business Wire's Website and the Associated Press Photo NetworkOpen in a New Window

PHOENIX--(BUSINESS WIRE)--Cigna and Express Scripts employees celebrated the combination of their companies by packing backpacks of food for children in Tempe, Arizona.

 

Medidata Named Best Workplace in Technology by Great Place to Work® and FORTUNEOpen in a New Window

NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Great Place to Work and FORTUNE named Medidata (NASDAQ:MDSO) one of the 2019 Best Workplaces in Technology. The company was selected 25th among large companies. The Best Workplaces in Technology provide excellent environments for all employees, regardless of position or other personal characteristics. Medidata employees (Medidatians) highly ranked the company’s atmosphere, rewards, and management transparency. “We are proud of the dedication our employees show to maki

 

Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive PartnerOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving Moderna to join Flagship Pioneering as an Executive Partner.

 

Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial OfficerOpen in a New Window

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics appoints Andrew Oxtoby as Chief Commercial Officer.

 

Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology TherapiesOpen in a New Window

BOSTON--(BUSINESS WIRE)--Kyn Therapeutics has entered into a global strategic collaboration with Celgene Corporation (NASDAQ:CELG) to develop novel immuno-oncology therapies.

 

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New SettingsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics announces strategic collaboration with Celgene to develop novel cell therapies with tunable immunomodulatory factors.

 

Teleflex to Showcase the MANTA™ Vascular Closure Device from the Recently Acquired Essential Medical, Inc. at the Annual Meeting of the Leipzig Interventional Course (LINC) 2019, in Leipzig, Germany, on January 22-25Open in a New Window

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex to showcase the MANTA Vascular Closure Device from the recently acquired Essential Medical, Inc. at the Annual Meeting of the LINC 2019

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect